CoChat

The Economics of Reproducibility in Preclinical Research

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible-in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pbio.1002165

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Studies reporting the prevalence of irreproducibility. Source: Begley and Ellis [6], Prinz et al. [7], Vasilevsky [8], Hartshorne and Schachner [5], and Glasziou et al. [9].
Fig 1 Studies reporting the prevalence of irreproducibility. Source: Begley and Ellis [6], Prinz et al. [7], Vasilevsky [8], Hartshorne and Schachner [5], and Glasziou et al. [9].CC BY · PubMed Central
Fig 2 Estimated US preclinical research spend and categories of errors that contribute to irreproducibility. Note that the percentage value of error for each category is the midpoint of the high and low prevalence estimates for that category divided (weighted) by the sum of all midpoint error rates (see S1 Dataset). Source: Chakma et al. [18] and the American Association for the Advancement of Science (AAAS) [19].
Fig 2 Estimated US preclinical research spend and categories of errors that contribute to irreproducibility. Note that the percentage value of error for each category is the midpoint of the high and low prevalence estimates for that category divided (weighted) by the sum of all midpoint error rates (see S1 Dataset). Source: Chakma et al. [18] and the American Association for the Advancement of Science (AAAS) [19].CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 1

  1. CF Manski, 2003, Springer Series in Statistics, 178

Cited by

Items 401–500 of 1,003

Metadata

Authors
Freedman, L. P., Cockburn, I. M., & Simcoe, T. S.
Affiliations
  • Global Biological Standards Institute (US)
  • Boston University (US)
Corresponding author
Freedman, Leonard P.
Venue
PLOS Biology
Published
2015-06-09
Volume
13
Issue
6
Pages
e1002165
ISSN
  • 1544-9173 (ISSN-L)
  • 1545-7885
OpenAlex
W585341442
Cited by
1,055
References
35
Citations by year
2026: 48 · 2025: 45 · 2024: 69 · 2023: 92 · 2022: 93 · 2021: 96 · 2020: 142 · 2019: 116 · 2018: 109 · 2017: 93 · 2016: 103 · 2015: 49
FWCI
188.58
Type
journal article
Language
en
Open access
Locations
  • PLoS Biology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • OpenBU (Boston University) (submittedVersion, cc-by)
Topics
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
  • Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
Keywords
reproducibility, preclinical research, research costs, research waste, reproducibility framework
MeSH terms
Reproducibility of Results, Biomedical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.